HLB테라퓨틱스

115450KOSDAQ

64.8 / 100

Reference Date: 2026-09-08

Financial Score21.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Therapeutics operates three core business divisions: biopharma, cold chain, and electronics. Through numerous mergers and acquisitions since 2013, the company has diversified its business, and after divesting its electronics division in 2024, it continues to transition toward a biopharma-focused structure. Its main revenue streams come from vaccine pharmaceuticals and distribution fees.

Number of Employees

50people

Average Salary

48.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.06Industry Average 1.204.0Point

In line with industry avg

ROE

-5.44Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

16.44Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲33.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -6.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
HLB테라퓨틱스, 각막염 신약 3상 마무리…11월 결과 공개
HLB테라퓨틱스의 신경영양성각막염 치료제 RGN-259가 글로벌 임상 3상을 성공적으로 완료하며 긍정적인 결과 기대.
Positive
HLB테라퓨틱스 'RGN-259' 임상 3상 종료…11월 톱라인 발표
HLB테라퓨틱스의 NK 치료제 RGN-259 임상 3상 성공으로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 2,080Won52-week high 3,98052-week low 1,451

1-month return4.0Point

1m +2.21% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 2Neutral 9Negative 0

Neutral전환가액의조정2026-09-04
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
Neutral주식등의대량보유상황보고서(일반)2026-09-04
Positive[기재정정]단일판매ㆍ공급계약체결2026-08-31
Neutral증권발행결과(자율공시)2026-08-31